表紙
市場調查報告書

遺傳基因檢驗的全球市場的預測:遺傳基因,新生兒,NIPT,腫瘤,藥物基因體學及DTC檢驗

The Global Genetic Testing Market by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic and Direct to Consumer. With Executive and Consultant Guides 2020 to 2024

出版商 Howe Sound Research 商品編碼 384217
出版日期 內容資訊 英文 391 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
遺傳基因檢驗的全球市場的預測:遺傳基因,新生兒,NIPT,腫瘤,藥物基因體學及DTC檢驗 The Global Genetic Testing Market by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic and Direct to Consumer. With Executive and Consultant Guides 2020 to 2024
出版日期: 2019年11月01日內容資訊: 英文 391 Pages
簡介

本報告提供全球遺傳基因檢驗市場相關調查分析,以14個國家、5地區為對象地,檢驗價格,數量預測,市場預測等相關的系統性資訊。

第1章 簡介與市場定義

  • 遺傳基因檢驗定義
  • 基因學革命
  • 市場定義
  • 美國的醫療市場、臨床檢驗:預測

第2章 市場概要

  • 市場參與企業的各種作用
    • 供應商/醫藥品
    • 獨立型實驗室 (特殊/專門)
    • 獨立型實驗室 (國家/地區)
    • 獨立型實驗室 (分析)
    • 公共實驗室 (國家/地區)
    • 醫院實驗室
    • 診療所實驗室
    • DTC實驗室
    • 獨立型遺傳基因檢驗實驗室
    • 審核團體
  • 遺傳基因檢驗:種類,案例,考察
    • 胚胎著床前遺傳基因診斷:新興市場
    • 產前診斷:新技術所創造的機會
    • 新生兒篩檢
    • 診斷檢驗
    • 電信業者檢驗
    • 預測/發病前檢驗
    • 藥物基因體學
    • 刑事鑑定
    • 親子鑑定
    • 祖先遺傳基因檢驗
  • 產業結構
    • 醫院檢驗的佔有率
    • 規模經濟
  • 主要企業的簡介
  • 主要企業的市場佔有率:分析

第3章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 檢查裝置、自動化
  • 診斷技術的發展

第4章 遺傳基因檢驗的最近的發展

第5章 各國市場規模:北美

  • 美國
  • 加拿大

第6章 各國市場:歐洲

  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 其他的歐洲,舊蘇聯

第7章 各國市場:亞太地區

  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 其他的亞太地區

第8章 各國市場:南美,非洲、中東

  • 巴西
  • 墨西哥
  • 其他南美
  • 非洲、中東

第9章 全球市場的摘要

  • 全球市場

第10章 遺傳基因檢驗的未來

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

OVERVIEW:

Will all newborns receive Whole Genomic Sequencing at birth? What key interest is driving Direct to Consumer?

Our facts and support = Your success.

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Genetic Testing Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Genetic Testing Definition in This Report
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Supplier/pharmaceutical
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Independent Genetic Testing Lab
    • 2.1.10 Audit Body
  • 2.2 Genetic Tests -Types, Examples and Discussion
    • 2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market
    • 2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity
    • 2.2.3 Newborn Screening
    • 2.2.2 Diagnostic Testing
    • 2.2.3 Carrier Testing
    • 2.2.6 Predictive and Presymptomatic Testing
    • 2.2.7 Pharmacogenomics
    • 2.2.8 Forensic Testing
    • 2.2.9 Parental Testing
    • 2.2.10 Ancestral Testing
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.2.1 Hospital vs. Central Lab
    • 2.3.3 Physician Office Lab's
    • 2.3.4 Physician's and POCT
  • 2.4 Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Genetic Discoveries Creating New Diagnostic Markets
    • 3.1.2 Aging Population a Boon for Diagnostics
    • 3.1.3 Pharmacogenomics Drives Further Growth.
    • 3.1.4 Oncology and Liquid Biopsy Enter New Era
    • 3.1.5 Fertility Practice Growth drives market
    • 3.1.6 Direct to Consumer begins to break out
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Testing usage analysis curtailing growth.
    • 3.2.4 Wellness has a downside
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role.
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution.
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 POCT/Self Testing Disruptive Force
    • 3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5 CGES Testing, A Brave New World
    • 3.4.6 Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1.1 Importance of This Section
  • 4.1.2 How to Use This Section
    • Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America
    • Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    • Phosphorus Offers DNA Testing to Assess Disease Risk
    • Arivale Shuts Down Personalized Wellness Business
    • ArcherDX Acquires Baby Genes
    • MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay
    • Thermo Fisher Purchases 9 Percent Stake in Yourgene Health
    • Invitae Partners to Expand Free Epilepsy Genetic Testing Program
    • Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx
    • NanoString Technologies Prices $103.5M Common Stock Offering
    • Canine Consumer Genomics Firm Embark Veterinary Raises $10M
    • Yourgene Health to Acquire Elucigene
    • Helix, AdventHealth Partner on Genetic Screening Study
    • Qiagen, NeuMoDx Ink Partnership, Merger Agreement
    • Prenetics Acquires DNAFit for $10M
    • Myriad Genetics to Acquire Counsyl for $375M
    • Roche inks $2.4B deal to buy out Foundation Medicine
    • Rapid genome sequencing could revolutionize health care
    • Scientists discover new nanoparticle, dubbed exomeres, released by tumors
    • New DNA tests look for 190 diseases in newborn's genetic code
    • Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia
    • New genetic risk score could help guide screening decisions for prostate cancer
    • Tele-genetics pilot makes genetic counseling accessible
    • Digital Genetic Assistant OptraGURU™ Launches Today from Optra Health
    • PacBridge Capital Partners Invests C$12M in Contextual Genomics
    • From DNA To Disease: A Diagnosis Made In Under A Day

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1 Global Market by Country
  • 6.2 Global Market by Application

7. Market Sizes by Application

  • 7.1 Hereditary Testing Market
  • 7.2 Newborn Testing Market
  • 7.3 NIPT Testing Market
  • 7.4 Oncology Testing Market
  • 7.5 Pharmacogenomic Testing Market
  • 7.6 Direct to Consumer Testing Market

8. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: January 2019 laboratory Fees Schedule
  • II Methodology
  • II.1 Authors
  • II.2 Sources

Table of Tables

  • Table 1 Most Common Traditional Genetic Disorders
  • Table 2 Lab Spending 2014 to 2024
  • Table 3 Market Players by Type
  • Table 4 The Different Types of Genetic Tests
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • TABLE 9 GLOBAL MARKET BY COUNTRY
  • TABLE 10 GLOBAL MARKET BY APPLICATION
  • TABLE 11 HEREDITARY SEGMENT BY COUNTRY
  • TABLE 12 NEWBORN SEGMENT BY COUNTRY
  • TABLE 13 NIPT SEGMENT BY COUNTRY
  • TABLE 14 ONCOLOGY SEGMENT BY COUNTRY
  • TABLE 15 PHARMACOGENOMIC SEGMENT BY COUNTRY
  • TABLE 16 DIRECT TO CONSUMER SEGMENT BY COUNTRY
  • Table 17 2019 CLINICAL LAB FEE SCHEDULE

Table of Figures

  • Figure 1 Clinical Lab Spending 2014 to 2024
  • Figure 2 Chart of 2017 Market Shares of Key Genetic Testing Companies
  • Figure 3 Top Ten Sequencing Companies
  • Figure 4 Percentage of World Population Over 65
  • Figure 5 Key Countries
  • FIGURE 6 APPLICATION SHARE BY YEAR
  • FIGURE 7 APPLICATION SEGMENT GROWTH RATES
  • FIGURE 8 SEGMENT SHARE SHIFTS
  • FIGURE 9 HEREDITARY VS. TOTAL MARKET GROWTH
  • FIGURE 10 NEWBORN VS. TOTAL MARKET GROWTH
  • FIGURE 11 NIPT VS. TOTAL MARKET GROWTH
  • FIGURE 12 ONCOLOGY VS. TOTAL MARKET GROWTH
  • FIGURE 13 PHARMACOGENOMIC VS. TOTAL MARKET GROWTH
  • FIGURE 14 DIRECT TO CONSUMER VS. TOTAL MARKET GROWTH
Back to Top